Published in J Urol on September 01, 1984
Medical Therapy of Prostatic Symptoms (MTOPS) | NCT00021814
The Effects of α-adrenergic Receptor Antagonists on Choroid and Pupil | NCT03144596
Thulium Laser Versus Bipolar Enucleation of the Prostate | NCT05200065
Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA (1992) 6.40
Oxidative stress in prostate cancer. Cancer Lett (2009) 2.28
Benign prostatic hyperplasia. Part 1--diagnosis. BMJ (2008) 1.70
Benign prostatic hyperplasia: an overview. Rev Urol (2005) 1.67
Benign prostatic hyperplasia. Br J Gen Pract (1997) 1.60
Estrogen and androgen signaling in the pathogenesis of BPH. Nat Rev Urol (2011) 1.52
Influence of immune inflammation on androgen receptor expression in benign prostatic hyperplasia tissue. Asian J Androl (2011) 1.51
Pioglitazone attenuates prostatic enlargement in diet-induced insulin-resistant rats by altering lipid distribution and hyperinsulinaemia. Br J Pharmacol (2010) 1.49
Inflammation and benign prostatic hyperplasia. Urol Clin North Am (2008) 1.44
Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation (2011) 1.42
Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis. World J Urol (2014) 1.40
Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest. Cell Death Differ (2010) 1.34
Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev (2009) 1.33
A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia. Proc Natl Acad Sci U S A (2009) 1.33
Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Br J Gen Pract (1993) 1.31
Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol (2004) 1.27
Elevated epithelial expression of interleukin-8 correlates with myofibroblast reactive stroma in benign prostatic hyperplasia. Urology (2008) 1.24
Transurethral microwave treatment for benign prostatic hypertrophy: a randomised controlled clinical trial. BMJ (1993) 1.19
The functional role of reactive stroma in benign prostatic hyperplasia. Differentiation (2011) 1.16
The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol Biomarkers Prev (2008) 1.15
Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol (2007) 1.14
Prostate kallikrein markers in diagnosis, risk stratification and prognosis. Nat Rev Urol (2009) 1.13
Estradiol causes the rapid accumulation of cAMP in human prostate. Proc Natl Acad Sci U S A (1994) 1.11
Prevalence of Benign Prostatic Hyperplasia on Jeju Island: Analysis from a Cross-sectional Community-based Survey. World J Mens Health (2012) 1.11
The effects of aging on the molecular and cellular composition of the prostate microenvironment. PLoS One (2010) 1.10
Multicenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensive medications. Clin Interv Aging (2015) 1.10
The expression of androgen-responsive genes is up-regulated in the epithelia of benign prostatic hyperplasia. Prostate (2009) 1.08
Intravesical prostatic protrusion in men in Olmsted County, Minnesota. J Urol (2009) 1.08
Testosterone and 17β-estradiol induce glandular prostatic growth, bladder outlet obstruction, and voiding dysfunction in male mice. Endocrinology (2012) 1.07
Mouse models of prostate cancer. Prostate Cancer (2011) 1.04
Inflammatory Mechanisms Associated with Prostatic Inflammation and Lower Urinary Tract Symptoms. Curr Prostate Rep (2008) 1.02
Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily. Clin Interv Aging (2008) 1.02
Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment. Differentiation (2013) 1.02
Impact of changing trends in medical therapy on surgery for benign prostatic hyperplasia over two decades. Korean J Urol (2012) 1.01
Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions. Int J Endocrinol (2014) 1.01
Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World J Urol (2011) 1.00
Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging. J Urol (2009) 1.00
Histotripsy methods in mechanical disintegration of tissue: towards clinical applications. Int J Hyperthermia (2015) 0.99
Metabolic syndrome and benign prostatic hyperplasia: evidence of a potential relationship, hypothesized etiology, and prevention. Korean J Urol (2011) 0.98
Stromally expressed c-Jun regulates proliferation of prostate epithelial cells. Am J Pathol (2007) 0.97
PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia. Differentiation (2011) 0.97
The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer. Cancer Causes Control (2010) 0.97
Incidence, predictors, and associated outcomes of prostatism after kidney transplantation. Clin J Am Soc Nephrol (2009) 0.97
Benign prostatic hyperplasia: from bench to clinic. Korean J Urol (2012) 0.96
Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Endocr Relat Cancer (2013) 0.96
Lower urinary tract symptoms in men. BMJ (2014) 0.95
Angiotensin II-mediated calcium signals and mitogenesis in human prostate stromal cell line hPCPs. Br J Pharmacol (2005) 0.94
Relationship between Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia and Metabolic Syndrome in Korean Men. World J Mens Health (2012) 0.94
Health seeking behavior for lower urinary tract symptoms in black men. J Urol (2008) 0.93
Silodosin is effective for treatment of LUTS in men with BPH: a systematic review. Asian J Androl (2012) 0.93
Relationship between metabolic syndrome and prostate volume in Korean men under 50 years of age. Korean J Urol (2011) 0.93
Prostate size correlates with fasting blood glucose in non-diabetic benign prostatic hyperplasia patients with normal testosterone levels. J Korean Med Sci (2011) 0.92
Relationships between Prostate-Specific Antigen, Prostate Volume, and Components of Metabolic Syndrome in Healthy Korean Men. Korean J Urol (2012) 0.92
Late-onset hypogonadism syndrome and lower urinary tract symptoms. Korean J Urol (2011) 0.91
TURIS plasma vaporization--initial Romanian experience with a new technology. J Med Life (2010) 0.91
Long-Term Follow-Up Results of Photoselective Vaporization of the Prostate with the 120 W Greenlight HPS Laser for Treatment of Benign Prostatic Hyperplasia. Korean J Urol (2011) 0.91
Benign prostatic hyperplasia: An overview of existing treatment. Indian J Pharmacol (2011) 0.91
Energy delivery systems for treatment of benign prostatic hyperplasia: an evidence-based analysis. Ont Health Technol Assess Ser (2006) 0.90
Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil. World J Mens Health (2013) 0.90
Potential involvement of P2Y2 receptor in diuresis of postobstructive uropathy in rats. Am J Physiol Renal Physiol (2009) 0.90
Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/β-catenin/TCF-4 complex inhibition of c-MYC transcription. Prostate (2014) 0.89
Transurethral resection of the prostate in Northern Nigeria, problems and prospects. BMC Urol (2008) 0.89
Anoctamin 1 (TMEM16A) is essential for testosterone-induced prostate hyperplasia. Proc Natl Acad Sci U S A (2015) 0.88
Pathophysiology of lower urinary tract symptoms in the aging male population. Rev Urol (2005) 0.88
Clinical value of prostate segmentation and volume determination on MRI in benign prostatic hyperplasia. Diagn Interv Radiol (2014) 0.88
Management of benign prostatic hyperplasia with silodosin. Open Access J Urol (2009) 0.87
Consultation patterns in a community survey of men with benign prostatic hyperplasia. Br J Gen Pract (1994) 0.87
Age-related changes in prostate zonal volumes as measured by high-resolution magnetic resonance imaging (MRI): a cross-sectional study in over 500 patients. BJU Int (2012) 0.86
Effects of electroacupuncture on benign prostate hyperplasia patients with lower urinary tract symptoms: a single-blinded, randomized controlled trial. Evid Based Complement Alternat Med (2011) 0.86
Medical management of lower urinary tract symptoms. Rev Urol (2009) 0.86
Psychosocial predictors of lower urinary tract symptom bother in black men: the Flint Men's Health Study. J Urol (2009) 0.86
Economic Evaluation Study (Cheer Compliant) Laser Prostatectomy for Benign Prostatic Hyperplasia: Outcomes and Cost-effectiveness. Medicine (Baltimore) (2016) 0.86
Is increased prostatic urethral angle related to lower urinary tract symptoms in males with benign prostatic hyperplasia/lower urinary tract symptoms? Korean J Urol (2012) 0.86
Evaluating men with benign prostatic hyperplasia. Rev Urol (2004) 0.85
5α-Reductase Isozymes in the Prostate. J Med Sci (2005) 0.85
5-alpha-Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia. Rev Urol (2003) 0.85
Validity of the "bother score" in the evaluation and treatment of symptomatic benign prostatic hyperplasia. Rev Urol (2005) 0.85
Treatment options for benign prostatic hyperplasia. Can Fam Physician (1997) 0.85
Epidemiology of lower urinary tract symptoms: emphasis on the status in Korea. Korean J Urol (2014) 0.84
Serum lipid levels in benign prostatic hyperplasia. World J Urol (2006) 0.84
Diastereomers of the brominated flame retardant 1,2-dibromo-4-(1,2 dibromoethyl)cyclohexane induce androgen receptor activation in the hepg2 hepatocellular carcinoma cell line and the lncap prostate cancer cell line. Environ Health Perspect (2009) 0.84
Overview of the Epidemiology of Lower Urinary Tract Dysfunction in South Korea. Int Neurourol J (2016) 0.84
Photoselective green-light laser vaporisation vs. TURP for BPH: meta-analysis. Asian J Androl (2012) 0.84
Relationship between age and prostate size. Asian J Androl (2012) 0.84
DNA methyl transferase 1 reduces expression of SRD5A2 in the aging adult prostate. Am J Pathol (2015) 0.83
Serum cytokine profiles in patients with prostate carcinoma. Exp Ther Med (2011) 0.83
Targeting stromal androgen receptor suppresses prolactin-driven benign prostatic hyperplasia (BPH). Mol Endocrinol (2013) 0.83
Estrogen receptor-α is a key mediator and therapeutic target for bladder complications of benign prostatic hyperplasia. J Urol (2014) 0.83
Preoperative Urinary Retention Increased the Risk of Urinary Retention after Photoselective Vaporization of the Prostate. World J Mens Health (2015) 0.83
Tamsulosin-induced severe hypotension during general anesthesia: a case report. J Med Case Rep (2010) 0.83
Polypharmacy in the HIV-infected older adult population. Clin Interv Aging (2013) 0.83
Effects of low-dose tamsulosin on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Korean J Urol (2013) 0.83
Molecular Basis of Steroid Action in the Prostate. Cellscience (2005) 0.83
180-W XPS GreenLight laser vaporization for benign prostate hyperplasia: 12-month safety and efficacy results for glands larger than 80 mL. Lasers Med Sci (2014) 0.83
Age-related histological and zinc content changes in adult nonhyperplastic prostate glands. Age (Dordr) (2013) 0.82
Managing benign prostatic hyperplasia in primary care. Patient-centred approach. Can Fam Physician (2000) 0.82
Testosterone and benign prostatic hyperplasia. Asian J Androl (2015) 0.82
Age-related changes in the innervation of the prostate gland: implications for prostate cancer initiation and progression. Organogenesis (2013) 0.82
The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians. Ther Adv Chronic Dis (2011) 0.82
Pathophysiology of benign prostatic hyperplasia in the aging male population. Rev Urol (2005) 0.81
Natural history of progression after PSA elevation following radical prostatectomy. JAMA (1999) 14.35
Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA (1994) 9.15
The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med (1992) 7.16
Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA (1992) 6.40
Identification of a nuclear protein matrix. Biochem Biophys Res Commun (1974) 5.41
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am (2001) 5.39
Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (1996) 5.06
The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol (1993) 4.55
Impotence following radical prostatectomy: insight into etiology and prevention. J Urol (1982) 4.08
Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology (2001) 3.99
Hereditary prostate cancer: epidemiologic and clinical features. J Urol (1993) 3.86
A fixed site of DNA replication in eucaryotic cells. Cell (1980) 3.78
Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate (1983) 3.53
Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A (1992) 3.28
Family history and the risk of prostate cancer. Prostate (1990) 3.27
Nuclear protein matrix: association with newly synthesized DNA. Science (1975) 3.27
Nuclear matrix. Isolation and characterization of a framework structure from rat liver nuclei. J Cell Biol (1977) 3.26
Supercoiled loops and eucaryotic DNA replicaton. Cell (1980) 3.24
Using prostate-specific antigen to diagnose prostate cancer: sailing in uncharted waters. Ann Intern Med (1993) 2.77
Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. JAMA (1997) 2.73
Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. N Engl J Med (1990) 2.67
Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer (1993) 2.40
Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology (2000) 2.35
Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol (2001) 2.32
Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med (1974) 2.27
Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl (1989) 2.12
Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am (1997) 2.07
The role of the nuclear matrix in the organization and function of DNA. Annu Rev Biophys Biophys Chem (1986) 2.07
Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology (1995) 2.00
DNA packaging and organization in mammalian spermatozoa: comparison with somatic cells. Biol Reprod (1991) 1.99
Considerations in the isolation of rat liver nuclear matrix, nuclear envelope, and pore complex lamina. Exp Cell Res (1981) 1.99
Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol (1996) 1.98
Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res (1993) 1.96
Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res (1996) 1.87
Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol (1988) 1.81
Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res (1981) 1.80
The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol (1982) 1.70
Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol (1998) 1.69
Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res (1995) 1.68
The prostate: an increasing medical problem. Prostate (1990) 1.67
The specific binding of estrogens and androgens to the nuclear matrix of sex hormone responsive tissues. J Biol Chem (1980) 1.66
Genetic susceptibility of benign prostatic hyperplasia. J Urol (1994) 1.66
Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987. J Urol (1990) 1.65
Radical prostatectomy and cystoprostatectomy with preservation of potency. Results using a new nerve-sparing technique. Br J Urol (1984) 1.63
Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. J Urol (1991) 1.63
An anatomical approach to the surgical management of the dorsal vein and Santorini's plexus during radical retropubic surgery. J Urol (1979) 1.63
Stem cell features of benign and malignant prostate epithelial cells. J Urol (1998) 1.62
Cystic lesions of the prostate gland. A sonographic--pathologic correlation. J Ultrasound Med (1990) 1.61
Biological aggressiveness of hereditary prostate cancer: long-term evaluation following radical prostatectomy. J Urol (1998) 1.60
Precise localization of the autonomic nerves from the pelvic plexus to the corpora cavernosa: a detailed anatomical study of the adult male pelvis. J Urol (1985) 1.58
Cavernous nerve grafts restore erectile function in denervated rats. J Urol (1991) 1.57
Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am J Pathol (1998) 1.57
Fourier analysis of cell motility: correlation of motility with metastatic potential. Proc Natl Acad Sci U S A (1989) 1.55
Cancer control following anatomical radical prostatectomy: an interim report. J Urol (1991) 1.55
The epidemiology of prostate cancer in Jamaica. J Urol (1998) 1.53
Idiopathic retroperitoneal fibrosis. J Urol (1979) 1.53
Future prospects in prostate cancer. Prostate (1999) 1.53
Disease progression following radical prostatectomy in men with Gleason score 7 tumor. J Urol (1998) 1.50
Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol (1990) 1.49
Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology (1994) 1.45
Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am (1993) 1.45
Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology (2000) 1.44
Pathological stage is higher in older men with clinical stage B1 adenocarcinoma of the prostate. J Urol (1989) 1.43
Polymerization of deoxyribonucleotides in relation to androgen-induced prostatic growth. Arch Biochem Biophys (1968) 1.43
A structural analysis of the role of the nuclear matrix and DNA loops in the organization of the nucleus and chromosome. J Cell Sci Suppl (1984) 1.43
The nuclear protein matrix: isolation, structure, and functions. Adv Enzyme Regul (1976) 1.41
Impact of anatomical radical prostatectomy on urinary continence. J Urol (1991) 1.41
Maintenance of advanced spermatogenic cells in the adult rat testis: quantitative relationship to testosterone concentration within the testis. Endocrinology (1989) 1.40
Linkage and association studies of prostate cancer susceptibility: evidence for linkage at 8p22-23. Am J Hum Genet (2001) 1.40
Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer (1991) 1.39
Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am (1990) 1.38
Adjuvant radiotherapy after radical prostatectomy: is it indicated? J Urol (1987) 1.38
Interaction between tetraethylthiuram disulfide and the sulfhydryl groups of D-amino acid oxidase and of hemoglobin. J Biol Chem (1966) 1.38
The induction of prostatic hypertrophy in the dog with androstanediol. J Clin Invest (1976) 1.38
Regulation of testicular function: a spatial and temporal view. Int Rev Physiol (1980) 1.35
Identification of nuclear matrix proteins in the cancer and normal rat prostate. Cancer Res (1991) 1.35
The influence of epididymal agenesis on the development and maturation of the testis: experimental model and clinical correlations. Urol Res (1984) 1.34
Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol (1998) 1.34
Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol (2000) 1.33
Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. J Urol (2001) 1.33
Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. J Urol (1993) 1.33
Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. Am J Hum Genet (2001) 1.32
Radical prostatectomy with preservation of sexual function: pathological findings in the first 100 cases. J Urol (1985) 1.32
Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. J Urol (1997) 1.32
Early cell motility changes associated with an increase in metastatic ability in rat prostatic cancer cells transfected with the v-Harvey-ras oncogene. Cancer Res (1988) 1.32
The role of androgens and estrogens in the pathogenesis of experimental nonbacterial prostatitis. J Urol (1988) 1.32
The role of radical prostatectomy in the management of prostatic cancer. Cancer (1987) 1.32
Newly replicated DNA is associated with DNA topoisomerase II in cultured rat prostatic adenocarcinoma cells. Nature (1986) 1.31
The incidence of intersexuality in patients with hypospadias and cryptorchidism. J Urol (1976) 1.31
Immunohistochemical localization of nitric oxide synthase in the autonomic innervation of the human penis. J Urol (1993) 1.28
Early age at diagnosis in families providing evidence of linkage to the hereditary prostate cancer locus (HPC1) on chromosome 1. Cancer Res (1997) 1.27
Nuclear-cytoskeletal interactions: evidence for physical connections between the nucleus and cell periphery and their alteration by transformation. J Cell Biochem (1992) 1.27
Correlation of nuclear morphometry with progression of breast cancer. Cancer (1991) 1.26
Cancer as a disease of DNA organization and dynamic cell structure. Cancer Res (1989) 1.24